雷公藤多甙联合福辛普利治疗小儿HSPN的疗效观察
发布时间：2019-03-31 19:00
【摘要】：本研究的为探讨雷公藤多甙联合福辛普利治疗小儿过敏性紫癜性肾炎(Henoch-Schonlein purpura nephritis,HSPN)的临床疗效及相关机制。选取2013年1月~2015年1月收入我院的94例过敏性紫癜性肾炎患儿,根据随机数字表法分为对照组和观察组,各47例。两组患者均给予常规内科治疗,对照组患儿在此基础上给予福辛普利钠,观察组患儿在对照组的基础上给予雷公藤多甙片。比较两组患儿的临床资料。治疗后,比较两组患儿免疫球蛋白水平、PT、APPT、PLT、FIB水平的变化情况。观察组的总有效率显著高于对照组,且复发率显著低于对照组(p0.05)。观察组的收缩压、舒张压、24 h尿蛋白量及腹痛、关节疼痛和水肿消失时间等临床症状的改善均显著优于对照组(p0.05)。治疗后,两组患者Ig A水平均显著降低(p0.05),且观察组较对照组降低更明显(p0.05);对照组PT较治疗前无明显改变(p0.05),而观察组PT则显著升高(p0.05),组间比较差异显著(p0.05);两组患者PLT较治疗前均显著降低(p0.05),且观察组较对照组降低更明显,组间比较差异显著(p0.05)。雷公藤多甙联合福辛普利对小儿HSPN临床疗效较好,可显著改善患者症状,其机制可能与降低Ig A水平、抑制细胞免疫、升高PT、降低PLT计数,以及改善凝血功能相关。
[Abstract]:The purpose of this study was to investigate the clinical efficacy and mechanism of tripterygium wilfordii polyglycoside combined with fosinopril in the treatment of Henoch-Schonlein purpura nephritis (Henoch-Schonlein purpura nephritis,HSPN) in children. From January 2013 to January 2015, 94 children with Henoch-Schonlein purpura nephritis (Henoch-Schonlein purpura nephritis) were divided into control group (n = 47) and observation group (n = 47). The children in the control group were given fosinopril sodium and the children in the observation group were given tripterygium wilfordii polyglycoside tablets on the basis of the control group. The clinical data of the two groups were compared. After treatment, the levels of immunoglobulin and PT,APPT,PLT,FIB were compared between the two groups. The total effective rate of the observation group was significantly higher than that of the control group, and the recurrence rate was significantly lower than the control group (p0.05). The improvement of systolic blood pressure, diastolic pressure, 24-hour urinary protein, abdominal pain, joint pain and disappearance time of edema in the observation group were significantly better than those in the control group (p0.05). After treatment, the level of Ig A in the two groups decreased significantly (p0.05), and the level in the observation group was more significantly lower than that in the control group (p0.05). The PT in the control group had no significant change compared with that before treatment (p0.05), but the PT in the observation group increased significantly (p0.05), and the difference between the two groups was significant (p0.05). The PLT of the two groups was significantly lower than that of the control group (p0.05), and that of the observation group was more obvious than that of the control group, and the difference between the two groups was significant (p0.05). Tripterygium wilfordii polyglycoside combined with fosinopril can significantly improve the symptoms of children with HSPN. The mechanism may be related to the decrease of Ig A level, inhibition of cellular immunity, increase of PT, and decrease of PLT count, as well as improvement of coagulation function.
【作者单位】： 内蒙古医科大学附属医院;
【分类号】：R726.9
本文编号：2451189
[Abstract]:The purpose of this study was to investigate the clinical efficacy and mechanism of tripterygium wilfordii polyglycoside combined with fosinopril in the treatment of Henoch-Schonlein purpura nephritis (Henoch-Schonlein purpura nephritis,HSPN) in children. From January 2013 to January 2015, 94 children with Henoch-Schonlein purpura nephritis (Henoch-Schonlein purpura nephritis) were divided into control group (n = 47) and observation group (n = 47). The children in the control group were given fosinopril sodium and the children in the observation group were given tripterygium wilfordii polyglycoside tablets on the basis of the control group. The clinical data of the two groups were compared. After treatment, the levels of immunoglobulin and PT,APPT,PLT,FIB were compared between the two groups. The total effective rate of the observation group was significantly higher than that of the control group, and the recurrence rate was significantly lower than the control group (p0.05). The improvement of systolic blood pressure, diastolic pressure, 24-hour urinary protein, abdominal pain, joint pain and disappearance time of edema in the observation group were significantly better than those in the control group (p0.05). After treatment, the level of Ig A in the two groups decreased significantly (p0.05), and the level in the observation group was more significantly lower than that in the control group (p0.05). The PT in the control group had no significant change compared with that before treatment (p0.05), but the PT in the observation group increased significantly (p0.05), and the difference between the two groups was significant (p0.05). The PLT of the two groups was significantly lower than that of the control group (p0.05), and that of the observation group was more obvious than that of the control group, and the difference between the two groups was significant (p0.05). Tripterygium wilfordii polyglycoside combined with fosinopril can significantly improve the symptoms of children with HSPN. The mechanism may be related to the decrease of Ig A level, inhibition of cellular immunity, increase of PT, and decrease of PLT count, as well as improvement of coagulation function.
【作者单位】： 内蒙古医科大学附属医院;
【分类号】：R726.9
【相似文献】
相关期刊论文 前6条
1 廖欣;高岩;杨华彬;钟桴;邓颖敏;赵明奇;赵小媛;;福辛普利治疗儿童慢性肾脏病的疗效[J];实用儿科临床杂志;2011年05期
2 张映红;福辛普利对心力衰竭患儿肿瘤坏死因子-α的影响[J];中国现代医学杂志;2003年06期
3 程雁;;福辛普利治疗慢性肾脏疾病[J];实用儿科临床杂志;2006年05期
4 王丽娜;于力;郝志宏;翁志媛;;福辛普利对肾小球系膜细胞层粘连蛋白及mRNA表达的影响[J];中国全科医学;2006年13期
5 于力;郝志宏;王丽娜;翁志媛;张蕾;张又祥;;Ⅳ型胶原和金属蛋白酶组织抑制剂-1在肾小球系膜细胞中的表达及福辛普利干预的意义[J];实用儿科临床杂志;2008年17期
6 ;[J];;年期
相关硕士学位论文 前1条
1 王云;福辛普利联合缬沙坦治疗IgA肾病患儿的疗效及其对尿转化生长因子β1水平的影响[D];安徽医科大学;2015年
，本文编号：2451189
本文链接：https://www.wllwen.com/yixuelunwen/eklw/2451189.html
最近更新
教材专著
